INTRODUCTION
The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated that regular prostate-specific antigen (PSA) screening every 2-4 years leads to a relative reduction in prostate cancer (PC)-specific mortality of 21% at 13 years of follow-up. 1 However, this benefit is offset by harms, in terms of over-diagnosis and consequent side-effects from treatment, hence the clear recommendation against PSA screening from the United States Preventive Services Task Force in 2012. 2 Using MIcrosimulation SCreening ANalysis (MISCAN), we have previously shown that over a lifetime, screening leads to a 28% relative reduction in PC-specific mortality and 8.4 life-years gained per averted death. 3 However, this benefit is mitigated by a loss in quality-adjusted life-years (QALYs)-a 23% reduction from life-years gained-primarily because of side-effects of treatment such as urinary and erectile dysfunction. 3 There have been considerable advances in our understanding of PC and PSA since the ERSPC was initiated in the early 1990s. Empirical data suggest that the ratio of benefit-to-harm could be improved by restricting screening to appropriate age ranges, restricting biopsy and treatment to men at highest risk, and shifting treatment to higher-volume centers. [4] [5] [6] These relatively uncontroversial findings have been incorporated in many guidelines. In contrast, research into common clinical practice has found frequent PSA testing among older men with limited life expectancy, [7] [8] aggressive use of curative treatment for low-risk tumors, 9 and surgical treatment largely performed by low-volume providers. 10 We hypothesize that the benefit-to-harm ratio from PSA screening and subsequent treatment would be improved by following a straightforward set of simple good practice guidelines.
We sought to quantify the effects of implementing these recommendations upon the outcomes of PC screening using MISCAN. We compared a "recommended good practice" model versus a model reflecting common screening and treatment practices, with a base model using ERSPC data.
METHODS

MISCAN
The MISCAN model, described in detail elsewhere, 3 simulates individual life histories with and without PSA screening, and with and without development of PC. The "tumor growth model" simulates PC natural history, which progresses from no disease, to preclinical screen-detectable PC, to clinical cancer at various stages. Thereafter, the tumor is screen-detected, clinically diagnosed, or progresses to another stage. The model is calibrated using raw data from the core age group (55-69 years) of the Rotterdam and Göteborg sections of the ERSPC. This includes follow-up data through 2008 (median 11 years) and a stage-dependent cure rate estimated for the observed PCspecific mortality reduction of 29% among attendees to screening in ERSPC. 3 The model was subsequently validated using data from all centra in the ERSPC, for both the screening and the control arms (thus accounting for a low contamination rate), as described earlier. 3 The effectiveness of radical prostatectomy (RP) compared to watchful waiting was assigned a relative risk of PC-specific mortality of 0.65 based on Scandinavian Prostate Cancer Group-4 data 11 ; a similar effect was assumed for radiotherapy (RT). Survival was modeled using the Gleason score−dependent Albertsen data 12 as well as Surveillance, Epidemiology, and End Results (SEER) data.
Model building
MISCAN relies on certain parameter inputs, which can be changed. We simulated lifetime outcomes for those who underwent PSA screening versus controls who did not undergo screening, for a male population aged 0 to 100 years, with an age distribution based on the European Standard Population. 3 We changed some of MISCAN's inputs to investigate the effects of the different models upon QALYs.
The base model uses annual PSA screening, as often practiced in the U.S. It follows a population of men aged 0-100 over their lifetimes and screens them, with 80% participation rate, between ages 55 and 69; matching the ERSPC core age group where a significant effect on PCspecific mortality was demonstrated in favor of screening. 1, [14] [15] The base model also uses: positive predictive value (PPV) of biopsy of 22.7% as in the ERSPC; primary treatment distribution (RP, RT, or AS with deferred treatment) based on age, T-stage and Gleason score as in the ERSPC; and complication rates after curative treatment as seen in U.S. population-based series. 3 We created 2 additional models: "recommended good practice," which amended the base model by incorporating 4 simple recommendations on screening and treatment found in many guidelines, and "common practice," in which we incorporated data from empirical studies of contemporary U.S. practice patterns. Table 1 lists the assumptions changed from the base model.
Age for screening. The ERSPC found no evidence of benefit for men who start PSA screening at age ≥70, with the lower bound of the 95% CI excluding the central estimate for risk reduction for men aged <70. 15 Similarly, the American Urological Association does not recommend routine PSA screening in men aged ≥70 years. 16 For the common practice model, where some men were assumed to continue screening after age 70, we used age-dependent screening rates from an empirical study of health behaviors in the U.S.: ages 70-74: 47%; 75-79: 44%; 80-84: 43%; 85+:
26%. 7 As that study included all ages over 84 into a single category, we assumed the 26% rate of screening for this category applied to ages 85-90, with no screening above age 90.
Biopsy criteria. The ERSPC study protocol stated that men with a positive screening test (PSA ≥ 3.0 ng/mL) should be recommended for biopsy. The proportion of test-positive men who had evidence of cancer on biopsy was only 22.7%. 14 In common urologic clinical practice, patients with elevated PSA are evaluated for benign disease and subject to repeat PSA testing before the decision to biopsy. 17 We investigated how screening outcomes would change if men with elevated PSA were biopsied more selectively, based on clinical work-up. Instead of a PPV of 22.7% for biopsy after a positive PSA test, we applied a PPV of 40%, in line with U.S. clinical cohorts, 18 for both the "recommended good practice" model and the "common practice" model.
Active surveillance (AS). Recent data clearly indicate that not all men with PC need
immediate treatment, and low-risk tumors can be safely managed by the approach known as active surveillance, with repeat biopsy and routine monitoring of the disease.
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Several guideline groups, such as the National Comprehensive Cancer Network, now recommend AS for low-risk PC. 17 We investigated how QALYs were affected if men with low-risk disease (clinical stage T1, Gleason score 6) were enrolled in AS. In the base model, AS usage depended on age, and averaged 30% across all men with low-risk tumors. For cumulative proportions of men leaving AS each year, we used data from Klotz's series: year 1: 8%, year 2: 16%, year 3: 20%, year 4: 24%, year 5: 28%, year 6: 29%, and year 7: 30%. 19 For the recommended good practice model, we applied a 90% rather than a 100% AS rate to men with low-risk disease, given that there may be clinical reasons to treat some low-risk men. For the common practice model, we applied an AS rate of 9.2% for men with low-risk disease, High-volume centers. There is a considerable literature on the volume-outcome relationship, suggesting decreased complications and side-effects and improved outcomes for patients treated by high-volume providers. [20] [21] [22] [23] Shifting treatment trends so that more patients are treated by highvolume surgeons could, therefore, possibly improve cancer control and decrease complications.
There have been widespread calls for "regionalization"
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; that is, increasing the proportion of patients treated at high-volume centers. 25 We investigated how QALYs were affected if impotence and incontinence rates after RP were in line with rates seen at high-volume centers. 26 The MISCAN model used a representative, multiregional, U.S. cohort as the source for estimates of overall sexual problems and urinary leakage problems at 24 months post-RP, taking baseline functioning into account. 27 The base model assumed 30% overall sexual bother, 6% urinary bother, and 0% bowel bother post-RP. 3 Although different rates were used for RT (20% sexual, 5% urinary, and 8% bowel bother), when multiplied with utilities, total utility ended up being similar for the two treatment modalities. These estimates may seem lower than many reported in the literature because they are marginal-that is, they take into account that some men would have dysfunction without surgery/ RT. Also, these estimates reflect bother not function, and not all men experiencing dysfunction report lowered utility.
Estimates for functional outcomes after RP for surgeons at a high-volume center were derived from empirical data using case-mix-adjusted outcomes, 26 , giving rates of sexual and leakage problems of 19% and 5%, respectively.
Sensitivity analysis
A sensitivity analysis was performed, comparing QALYs gained between the 3 models. In an attempt to reflect the effect of the different strategies on a population level, rather than an individual level, we varied the utility estimates (more vs less extreme) by about half those previously published.
We compared 5 different scenarios per model using different combinations of utilities for screening procedures versus treatment and terminal illness, ie, reflecting varying population-level trade-offs for tolerability of screening procedures versus down-stream consequences.
Since the use of AS for men with low-risk disease has increased over the past years, another sensitivity analysis was performed, with a 34% AS rate, as reported in a recent update from the CaPSURE registry for the time period 2008-2013. The predicted effects of the screening approaches are shown in Table 3 . Compared to the base model, recommended good practice led to an improvement in QALYs gained, from 56 to 74, largely related to increased use of AS. This approach also substantially reduced the number of biopsies performed, from 605 to 407 per 1000 men. In contrast, common practice with screening up to age 90 years and with a 9.2% AS rate, led to 78 life-years gained but only 19 QALYs gained.
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RESULTS
Effect of modeling on QALYs
This is more than a 75% relative reduction in QALYs gained from unadjusted life-years gained. Of the QALYs lost by following common practice compared to recommended good practice, about 24
were related to overtreatment of low-risk disease, 34 due to screening older men, and 3 due to treatment at low-volume centers ( Table 4 ). Note that these figures do not add up to the 55 QALY difference between common practice and recommended good practice because of interaction effects, such as the impact of overtreatment in older men.
In a sensitivity analysis varying the more and less extreme utility estimates in an attempt to reflect the effect on QALYs of the different strategies at a population level, did not show recommended good practice leading to worse outcomes than the base or common practice models (Supplementary material).
Increasing the use of AS to 34%, to reflect more contemporaneous rates, yielded an overall 30 QALYs gained for current practice compared to 74 QALYs for recommended good practice.
DISCUSSION
This study examined the effect upon QALYs of widespread implementation of 4 widely-accepted screening and treatment recommendations, compared to common clinical practice.
Microsimulation modeling showed that care following the good practice recommendationsrestricting screening in elderly men, selective biopsy, AS for low risk tumors and preferential referral to high-volume centers -led to a large improvement in QALYs gained per 1000 men, up to 74 from 56 for the base model. In contrast, common screening and treatment practice was estimated to lead to only 19 QALYs gained, translating into a more than 75% relative loss in potential QALYs gained.
Naturally, any modeling study is only as good as the model used. The MISCAN model has been shown to adequately predict PC incidence and PC-specific mortality in the Netherlands. 3 When applied to the U.S. population and compared to other models, differences are relatively minor (eg, lead time of 7.9 vs. 6.9 years). In comparison with 2 other models, MISCAN may be conservative, that is, may overestimate some screening harms. 29 We have also previously argued 13 that the European data may underestimate the benefits of screening due to sub-optimal treatment efficacy in the ERSPC, where both radiation doses and surgeon volumes were much lower than would be optimal. 30 Note that we did not include higher cure rates associated with referral to highvolume centers in our "recommended good practice" model, perhaps underestimating the benefits for more regionalized care. Furthermore, the differences in urinary and sexual problems between standard care and care at high-volume centers were relatively modest in our model: 1% and 11%, respectively, in absolute terms. Again, this may lead to some underestimation of the effects of regionalized treatment.
There has been considerable recent interest in the use of risk-stratified methods of evaluating men with elevated PSA-levels before biopsy, such as reflex blood tests or multiparametric magnetic resonance imaging. The PPV associated with these tests is likely even higher than the 40% figure used in our models. The QALYs gained with recommended good practice may, therefore, be a slight underestimation. However, we do not expect this to make a large difference to our findings as the near 20-point increase in PPV used in the main analysis led to only a minor improvement in QALYs gained (+1.2 QALYs).
There is some evidence that current practice is changing. Across community-based urology practices in Michigan, half of men with low-risk PC now receive initial AS. 31 We expect there will be more pronounced changes throughout the U.S. in the near future. Changing the use of AS to 34%, as reported in the most recent update from the CaPSURE registry, 28 did increase overall QALYs gained from 19 to 30. These are promising signs that changes in urologic practice will make a large difference to quality-of-life outcomes of screening.
There is also evidence that screening practices in older men have been changing for the better. For instance, incidence data from SEER have indicated that the age-, race-and ethnicity- 32 While encouraging, these changes go only a small way toward the major shift in screening and treatment practices needed for U.S. practice to be compliant with good practice recommendations.
Critics of PSA screening claim that it has little benefit and causes significant harm. This may be the case as PSA screening is currently implemented in the US, but does not take into account the potential benefit of screening that follows good practice recommendations. Addressing the problems of screening in older men and aggressive treatment of low-risk disease might be expected to strongly increase the benefit of PSA screening.
A limitation of the present study is that results based on the MISCAN model are relevant for
Caucasian men and may not apply to men of other ethnicities.
CONCLUSIONS
Common practices for PSA screening and subsequent PC treatment are associated with considerable harm and moderate benefit. Changing practices to conform to established recommendations would lead to an estimated 4-fold increase in the net benefit of screening. The more and less extreme utilities used for the sensitivity analysis are assumed to be half those previously reported, to reflect the effects of a policy on a population level, rather than the effects on the individual level. In the base model, screening men between the ages of 55-69 years yields 56 QALYs gained over a lifetime. This is based on assumptions of the utilities for the modeled health states; screening attendance, biopsy, diagnosis, treatment, post-recovery period, palliative treatment, and terminal illness. These utilities can be varied from less extreme to more extreme values ( 
